Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

IntroductionThe Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations.MethodsThe working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements.ResultsParticipants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

[1]  T. Livraghi,et al.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.

[2]  藤田 みさお.  「肝右葉切除術による成人間生体肝移植」, Trotter JF, Wachs M, Everson GT, et al, Adult-to-adult transolantation of the right hepatic lobe from a living donor, N Engl J Med 346, 1074-1082, 2002 , 2003 .

[3]  H. Yamane,et al.  Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 , 1995, Nature.

[4]  C. J. Chen,et al.  Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. , 2000, Journal of the National Cancer Institute.

[5]  V. Wong,et al.  High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jeffrey S. Morris,et al.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma , 2007, Cancer.

[7]  T. Murakami,et al.  Detection of hepatocellular carcinoma in patients with cirrhosis: MR imaging versus angiographically assisted helical CT. , 1997, AJR. American journal of roentgenology.

[8]  Sheng-Nan Lu,et al.  Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. , 2007, Gastroenterology.

[9]  A. Pezzoli,et al.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. , 1996, Journal of hepatology.

[10]  T. Maeda,et al.  Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha‐fetoprotein , 1994, Cancer.

[11]  A. Terano,et al.  Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. , 1993, AJR. American journal of roentgenology.

[12]  S. Fan,et al.  A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma , 2007, Annals of surgery.

[13]  Sheng-Nan Lu,et al.  Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus , 2005, Journal of gastroenterology and hepatology.

[14]  J. Dodd,et al.  Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization? , 2005, Radiology.

[15]  T. Murakami,et al.  Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.

[16]  Michiie Sakamoto,et al.  Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection , 1996, Cancer.

[17]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[18]  B. Furie,et al.  Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. , 1984, The New England journal of medicine.

[19]  K. Okuda,et al.  Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma , 2003, Cancer.

[20]  H. Honda,et al.  Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. , 2002, AJR. American journal of roentgenology.

[21]  H. J. de Silva,et al.  How should we manage patients with non‐alcoholic fatty liver disease in 2007? , 2007, Journal of gastroenterology and hepatology.

[22]  E. Keeffe,et al.  Racial differences in effectiveness of α‐fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis , 2002, Hepatology.

[23]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[24]  Hung-Sheng Chen,et al.  Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma , 2005 .

[25]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[26]  T. Ogihara,et al.  Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes , 1993, Digestive Diseases and Sciences.

[27]  T. Pawlik,et al.  Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. , 2005, Surgery.

[28]  Junji Kato,et al.  Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor-κB , 2006, Gut.

[29]  Carlo Bartolozzi,et al.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.

[30]  Y. Ohashi,et al.  Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival , 2005, Annals of Internal Medicine.

[31]  F. Callea,et al.  Pathology of hepatocellular carcinoma , 1993, Journal of surgical oncology. Supplement.

[32]  B. McMahon,et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.

[33]  O. Matsui,et al.  Extrahepatic Blood Supply to Hepatocellular Carcinoma: Angiographic Demonstration and Transcatheter Arterial Chemoembolization , 2006, CardioVascular and Interventional Radiology.

[34]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Toshihito Seki,et al.  Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma , 1994, Cancer.

[37]  T. Livraghi,et al.  US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. , 1986, Radiology.

[38]  T. Saibara,et al.  Transactivation of Transforming Growth Factor α Gene by Hepatitis B Virus preS1 , 1998 .

[39]  C. la Vecchia,et al.  Coffee drinking and hepatocellular carcinoma risk: A meta‐analysis , 2007, Hepatology.

[40]  E. Abdalla,et al.  Resection Prior to Liver Transplantation for Hepatocellular Carcinoma , 2003, Annals of surgery.

[41]  Tsang-En Wang,et al.  Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[42]  Ryutaro Hirose,et al.  Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis , 2008, Hepatology.

[43]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[44]  E. Caturelli,et al.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. , 2000, Radiology.

[45]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[46]  J. Marrero,et al.  Diagnosis and treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[47]  L. Saltz,et al.  3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma , 2007 .

[48]  H. Hsu,et al.  Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. , 2000, JAMA.

[49]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[50]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[51]  F. Nomura,et al.  Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. , 1996, The American journal of gastroenterology.

[52]  K. Hayashi,et al.  Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus‐related hepatocellular carcinoma , 2007, Journal of gastroenterology and hepatology.

[53]  J. Pignon,et al.  Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial , 2007, British Journal of Cancer.

[54]  P Neuhaus,et al.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.

[55]  F. Callea,et al.  Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[56]  A. Tamori,et al.  Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. , 2004, JAMA.

[57]  Y. Cho,et al.  The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  Chee-Kin Hui,et al.  Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis‐related complications, and hepatocellular carcinoma , 2003, Hepatology.

[59]  T. Hibi,et al.  Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. , 2005, Hepato-gastroenterology.

[60]  R. Goldberg,et al.  Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma , 2008 .

[61]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[62]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[63]  Sheng-Nan Lu,et al.  A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan , 2006, Antiviral therapy.

[64]  F. Donato,et al.  Radiofrequency ablation of hepatocellular carcinoma: long-term experience with expandable needle electrodes. , 2006, AJR. American journal of roentgenology.

[65]  G Realdi,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). , 1997, Journal of hepatology.

[66]  M. Cottone,et al.  Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. , 1994, Journal of hepatology.

[67]  Chih‐Hsin Yang.  EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. , 2008, Lung cancer.

[68]  Shinpei Sato,et al.  Percutaneous radiofrequency ablation for hepatocellular carcinoma , 2005, Cancer.

[69]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[70]  T. Waldmann,et al.  α-Fetoprotein in Nonneoplastic Hepatic Disorders , 1975 .

[71]  P. Schirmacher,et al.  Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.

[72]  M. Kudo,et al.  Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin‐reactive α‐fetoprotein 1 , 2001, Journal of gastroenterology and hepatology.

[73]  M. Goldman.  Determinants of outcome of compensated hepatitis C virus related cirrhosis , 1999 .

[74]  C-J. S. Lin,et al.  Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less , 2005, Gut.

[75]  M. Makuuchi,et al.  Bile duct necrosis: complication of transcatheter hepatic arterial embolization. , 1985, Radiology.

[76]  S. Fan,et al.  Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. , 2002, Journal of the American College of Surgeons.

[77]  N. Moriyama,et al.  Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. , 1997, Japanese journal of clinical oncology.

[78]  Masatoshi Kudo,et al.  Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology , 2007, Oncology.

[79]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[80]  C. J. Chen,et al.  Hepatitis B virus e antigen and primary hepatocellular carcinoma. , 1991, Anticancer research.

[81]  L. Mariani,et al.  Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis , 2006, Hepatology.

[82]  H. Aburatani,et al.  Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma , 2004, Cancer Research.

[83]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[84]  M. Kudo,et al.  Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. , 2001, Radiology.

[85]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[86]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[87]  G. Strickland.  Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors , 2006, Hepatology.

[88]  S. Larsson,et al.  Coffee consumption and risk of liver cancer: a meta-analysis. , 2007, Gastroenterology.

[89]  Luigi Solbiati,et al.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.

[90]  U. Iloeje,et al.  Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study , 2006, The American Journal of Gastroenterology.

[91]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[92]  H. Fukuda,et al.  Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. , 2005, Journal of hepatology.

[93]  Carlo Bartolozzi,et al.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. , 2005, Radiology.

[94]  M. Hebbar,et al.  Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma , 2008, Cancer.

[95]  H. Hussain,et al.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  O. Goletti,et al.  PERCUTANEOUS ETHANOL INJECTION IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA , 1992 .

[97]  R. D. de Man,et al.  Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B , 2004, Hepatology.

[98]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[99]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[100]  K. Ikeda,et al.  Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma – direct ablative effects and a long‐term outcome , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[101]  Chien-Jen Chen,et al.  Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. , 2003, American journal of epidemiology.

[102]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[103]  S. Fan,et al.  Hepatic resection for bilobar hepatocellular carcinoma: is it justified? , 2003, Archives of surgery.

[104]  M. Fujita,et al.  Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. , 1992, Radiology.

[105]  R. Yokoyama,et al.  Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography. , 1997, AJR. American journal of roentgenology.

[106]  Ching-lung Lai,et al.  Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial , 1988, Cancer.

[107]  K. McGlynn,et al.  Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. , 2004, Gastroenterology.

[108]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[109]  M. Yuen,et al.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. , 2009, Journal of hepatology.

[110]  H. Moriwaki,et al.  Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma , 1998, Digestion.

[111]  Y. Liaw,et al.  Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors , 2004, Cancer.

[112]  D. Trichopoulos,et al.  Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. , 1991, JAMA.

[113]  H. Yoshizawa.  Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future , 2002, Oncology.

[114]  R. G. Parrish,et al.  Hemochromatosis-Associated Mortality in the United States from 1979 to 1992: An Analysis of Multiple-Cause Mortality Data , 1998, Annals of Internal Medicine.

[115]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[116]  Kenichi Kobayashi,et al.  Screening methods for early detection of hepatocellular carcinoma , 1985, Hepatology.

[117]  J. Everhart,et al.  Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. , 2005, Gastroenterology.

[118]  M. Choi,et al.  Long-term Results of Percutaneous Ethanol Injection for the Treatment of Hepatocellular Carcinoma in Korea , 2006, Korean journal of radiology.

[119]  Jung-Hwan Yoon,et al.  Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients , 2006, Korean journal of radiology.

[120]  Rita Golfieri,et al.  Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma , 2005, Hepatology.

[121]  Y. Shiratori,et al.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation , 2004, Hepatology.

[122]  F. Chisari,et al.  Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis. , 1997, Cancer research.

[123]  K. Buetow,et al.  Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. , 1995, Intervirology.

[124]  Yukihiro Koike,et al.  Nonsurgical Treatment of Hepatocellular Carcinoma: From Percutaneous Ethanol Injection Therapy and Percutaneous Microwave Coagulation Therapy to Radiofrequency Ablation , 2002, Oncology.

[125]  J. Wong,et al.  Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. , 2000, Annals of surgery.

[126]  K. Owzar,et al.  Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301 , 2007 .

[127]  K. Kowdley.  Iron, hemochromatosis, and hepatocellular carcinoma. , 2004, Gastroenterology.

[128]  I. Penn.  Hepatic transplantation for primary and metastatic cancers of the liver. , 1991, Surgery.

[129]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[130]  W. London,et al.  Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[131]  E. Feller,et al.  Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. , 1978, Gastroenterology.

[132]  M. Kudo,et al.  Sonography with intraarterial infusion of carbon dioxide microbubbles (sonographic angiography): value in differential diagnosis of hepatic tumors. , 1992, AJR. American journal of roentgenology.

[133]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[134]  M. Sherman,et al.  Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population , 1995, Hepatology.

[135]  A. Lok,et al.  α‐fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma , 1989, Hepatology.

[136]  R. Hultcrantz,et al.  Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. , 2003, Gastroenterology.

[137]  C. Chen,et al.  Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma , 1996, Hepatology.

[138]  R. Lencioni,et al.  Treatment before Liver Transplantation for HCC , 2008, Annals of Surgical Oncology.

[139]  E. Taioli,et al.  A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. , 1998, Blood.

[140]  P. Parrilla,et al.  Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? , 2003, Transplantation Proceedings.

[141]  K. Tanikawa,et al.  A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis , 1989, Gastroenterologia Japonica.

[142]  S. Hadziyannis,et al.  Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.

[143]  D. V. van Thiel,et al.  The development of de novo hepatocellular carcinoma in patients on a liver transplant list: Frequency, size, and assessment of current screening methods , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[144]  Shinji Tanaka,et al.  Molecular targeted therapies in hepatocellular carcinoma. , 2012, Seminars in oncology.

[145]  N. Hotta,et al.  Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. , 2007, Hepato-gastroenterology.

[146]  Chien-Jen Chen,et al.  Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. , 2008, Gastroenterology.

[147]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[148]  M. Soresi,et al.  Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. , 2003, Anticancer research.

[149]  Jian-Min Yuan,et al.  Environmental factors and risk for hepatocellular carcinoma. , 2004, Gastroenterology.

[150]  Sheng-Nan Lu,et al.  Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection , 1999, Cancer.

[151]  N. Tanaka,et al.  Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma , 1999, American Journal of Gastroenterology.

[152]  C. Porta,et al.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  S. Paik,et al.  Combined Hepatectomy and Radiofrequency Ablation for Multifocal Hepatocellular Carcinomas: Long-term Follow-up Results and Prognostic Factors , 2007, Annals of Surgical Oncology.

[154]  E. Negri,et al.  Liver cirrhosis and the risk of primary liver cancer , 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[155]  V. Vilgrain,et al.  Small Nodule Detection in Cirrhotic Livers: Evaluation with US, Spiral CT, and MRI and Correlation with Pathologic Examination of Explanted Liver , 2001, Journal of computer assisted tomography.

[156]  Z. Chen,et al.  Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma , 2003, British Journal of Cancer.

[157]  M. Federle.  Use of radiologic techniques to screen for hepatocellular carcinoma. , 2002, Journal of clinical gastroenterology.

[158]  S. Fan,et al.  Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma , 2000, Cancer.

[159]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[160]  M. Shindo,et al.  Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy , 1999, Cancer.

[161]  Y. Imai,et al.  Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.

[162]  O. Yokosuka,et al.  Resolution of acute hepatitis C after therapy with natural beta interferon , 1991, The Lancet.

[163]  J. Jang,et al.  A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo‐lipiodolization , 2006, Hepatology.

[164]  Y. Itai,et al.  Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. , 2000, AJR. American journal of roentgenology.

[165]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[166]  C. Herfarth,et al.  Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. , 1998, Annals of surgery.

[167]  I. Rusyn,et al.  Protective effect of Juzen‐taiho‐to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell‐induced oxidative stress , 2008, International journal of cancer.

[168]  A. Shirahata,et al.  Vitamin K Contents in Liver Tissue of Hepatocellular Carcinoma Patients , 2000, Japanese journal of cancer research : Gann.

[169]  M. Coleman,et al.  Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan. , 1999, Annals of epidemiology.

[170]  S. Kar,et al.  Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin , 2000, Journal of cellular physiology.

[171]  T. Okanoue,et al.  A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. , 2001, Hepatology.

[172]  M. Kudo.  Imaging Diagnosis of Hepatocellular Carcinoma and Premalignant/Borderline Lesions , 1999, Seminars in liver disease.

[173]  Kuan‐Yang Chen,et al.  Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[174]  Chien-Jen Chen,et al.  The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case‐control study , 1992, Cancer.

[175]  S. Hashimoto,et al.  Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. , 1994, Biochemical and biophysical research communications.

[176]  Jae Young Lee,et al.  Hepatocellular Carcinoma in Cirrhotic Liver: Double-Contrast-Enhanced, High-Resolution 3.0T-MR Imaging With Pathologic Correlation , 2008, Investigative radiology.

[177]  H. Ding,et al.  Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein , 2003, British Journal of Cancer.

[178]  M. Kojiro,et al.  Pathologic Characteristics of Hepatocellular Carcinoma , 1986, Seminars in liver disease.

[179]  F. Becker,et al.  Alpha-Fetoprotein 3 , 1978 .

[180]  Manal M. Hassan,et al.  Thalidomide in the treatment of patients with hepatocellular carcinoma , 2005, Cancer.

[181]  N M Rofsky,et al.  Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. , 2001, Radiology.

[182]  Umberto Gelatti,et al.  Case‐control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol , 1999 .

[183]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[184]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.

[185]  Haitao Luo,et al.  Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[186]  G. Wogan.  Aflatoxins as risk factors for hepatocellular carcinoma in humans. , 1992, Cancer research.

[187]  M. Kedda,et al.  Dietary iron overload as a risk factor for hepatocellular carcinoma in black africans , 1998, Hepatology.

[188]  T. Pawlik,et al.  Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database , 2005, Annals of Surgical Oncology.

[189]  Dr. Chau Tai-Nin,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 2006 .

[190]  D. Choi,et al.  Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced mr imaging versus combined helical CT during arterial portography and CT hepatic arteriography. , 2001, AJR. American journal of roentgenology.

[191]  A. Tamori,et al.  Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.

[192]  A. Floreani,et al.  Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis , 1999, Cancer.

[193]  H. Hsu,et al.  Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. , 1996, JAMA.

[194]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[195]  R. Koretz,et al.  Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. , 2003, The American journal of medicine.

[196]  J M Rubin,et al.  Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US. , 1994, Radiology.

[197]  Wang Qi,et al.  Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma in Elderly Patients , 2009 .

[198]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[199]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[200]  Tae Kyoung Kim,et al.  Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology. , 2005, Clinics in liver disease.

[201]  M. Fujita,et al.  Color Doppler flow imaging of liver tumors. , 1990, AJR. American journal of roentgenology.

[202]  Chien-Jen Chen,et al.  Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan , 1996, International journal of cancer.

[203]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[204]  Jeong Min Lee,et al.  Diagnostic Accuracy of Multi-/Single-Detector Row CT and Contrast-Enhanced MRI in the Detection of Hepatocellular Carcinomas Meeting the Milan Criteria before Liver Transplantation , 2008, Intervirology.

[205]  Chien-Jen Chen,et al.  Secular trends and geographic variations of hepatitis B virus and hepatitis C virus‐associated hepatocellular carcinoma in Taiwan , 2006, International journal of cancer.

[206]  J. Sung,et al.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. , 1987, JAMA.

[207]  S. Hirohashi,et al.  Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. , 1998, Japanese journal of clinical oncology.

[208]  E. Raymond,et al.  Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) , 2007 .

[209]  M. Yuen,et al.  Long‐term follow‐up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis‐related complications , 2001, Hepatology.

[210]  T. Livraghi,et al.  Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. , 1997, Scandinavian journal of gastroenterology.

[211]  H. Shinmoto,et al.  Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arterioportography plus CT during hepatic arteriography , 2005, Journal of Gastroenterology.

[212]  Eleni Liapi,et al.  Transcatheter and ablative therapeutic approaches for solid malignancies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  J. Crespo,et al.  Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma , 2005, Obesity surgery.

[214]  M. Makuuchi,et al.  Uracil‐tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial , 2006, Hepatology.

[215]  L Solbiati,et al.  Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. , 1999, Radiology.

[216]  R. Yamada,et al.  Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.

[217]  H. Adami,et al.  Alcoholism and liver cirrhosis in the etiology of primary liver cancer , 1992, International journal of cancer.

[218]  B. Choi,et al.  Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. , 1996, Radiology.

[219]  S. Thorgeirsson,et al.  Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[220]  C. Chu,et al.  Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection , 1999, Hepatology.

[221]  Zongli Zhang,et al.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. , 2008, JAMA.

[222]  G. Everson,et al.  Adult-to-adult transplantation of the right hepatic lobe from a living donor. , 2002, The New England journal of medicine.

[223]  M. Sata,et al.  Answer , 2004, Gut.

[224]  M. Colombo,et al.  Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy , 2003, Hepatology.

[225]  克也 平山,et al.  A prospective randomized trial , 1995 .

[226]  C. J. Chen,et al.  A case‐control study of primary hepatocellular carcinoma in Taiwan , 1988, Cancer.

[227]  M. Thomas,et al.  The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) , 2007 .

[228]  M. Rosen,et al.  Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study , 2007 .

[229]  Ding‐Shinn Chen,et al.  High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. , 2006, Gastroenterology.

[230]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.

[231]  K. Tatara,et al.  Coffee consumption and decreased serum γ-glutamyltransferase: a study of middle-aged Japanese men , 2000, European Journal of Epidemiology.

[232]  Fuminori Moriyasu,et al.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. , 2007, Ultrasound in medicine & biology.

[233]  C. Kulli,et al.  Laparoscopic versus open liver segmentectomy: prospective, case-matched, intention-to-treat analysis of clinical outcomes and cost effectiveness , 2008, Surgical Endoscopy.

[234]  M. Kudo,et al.  Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. , 2004, AJR. American journal of roentgenology.

[235]  Kinuyo Hatanaka,et al.  Differential Diagnosis of Hepatic Tumors: Value of Contrast-Enhanced Harmonic Sonography Using the Newly Developed Contrast Agent, Sonazoid , 2008, Intervirology.

[236]  D. Häussinger,et al.  Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.

[237]  Yoshiyuki Suzuki,et al.  Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.

[238]  E. Jaurrieta,et al.  Selection criteria for liver transplantation in early‐stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[239]  M. Makuuchi,et al.  Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.

[240]  J. Tanaka,et al.  National Prevention of Hepatocellular Carcinoma in Japan Based on Epidemiology of Hepatitis C Virus Infection in the General Population , 2005, Intervirology.

[241]  T. Ono,et al.  Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. , 1985, Biochimica et biophysica acta.

[242]  S. Nakano,et al.  Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. , 1999, European journal of gastroenterology & hepatology.

[243]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[244]  E. Bass,et al.  Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review , 2002, Hepatology.

[245]  M. Sato,et al.  Hepatocellular carcinoma: involvement of the internal mammary artery. , 2001, Radiology.

[246]  M. Choti,et al.  Operative Mortality After Hepatic Resection: Are Literature-Based Rates Broadly Applicable? , 2007, Journal of Gastrointestinal Surgery.

[247]  A. Muratore,et al.  Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[248]  J. Bruix,et al.  Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection , 1993, Hepatology.

[249]  R. Epstein,et al.  Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): Final report , 2008 .

[250]  M. Sherman,et al.  Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis , 2007, The American Journal of Gastroenterology.

[251]  D. Lu,et al.  Hepatocellular carcinoma screening in patients waiting for liver transplantation: A decision analytic model , 2003, Liver transplantation.

[252]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[253]  Y. Shiratori,et al.  Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐ viral infection in Japan , 1995, Hepatology.

[254]  P. Hahnfeldt,et al.  In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. , 1993, Journal of vascular and interventional radiology : JVIR.

[255]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[256]  J. Bruix,et al.  Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.

[257]  M. Cappellini,et al.  Hepatocellular carcinoma in the thalassaemia syndromes , 2004, British journal of haematology.

[258]  Frederick Mosteller,et al.  Guidelines for Meta-analyses Evaluating Diagnostic Tests , 1994, Annals of Internal Medicine.

[259]  K. Madan,et al.  Evaluating Patients with Cirrhosis for Hepatocellular Carcinoma: Value of Clinical Symptomatology, Imaging and Alpha-Fetoprotein , 2007, Oncology.

[260]  H. Eguchi,et al.  Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. , 2000, Archives of surgery.

[261]  O. Matsui,et al.  Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. , 2002, Radiology.

[262]  Carmen Ayuso,et al.  MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation , 2003, Hepatology.

[263]  C. la Vecchia.  Coffee, liver enzymes, cirrhosis and liver cancer. , 2005, Journal of hepatology.

[264]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[265]  K. Chayama,et al.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis , 1999, Hepatology.

[266]  O. Farges,et al.  Is surgery for large hepatocellular carcinoma justified? , 1999, Journal of hepatology.

[267]  I. Sartori.  Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein: , 1994 .

[268]  Chien-Jen Chen,et al.  Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.

[269]  A. Lin,et al.  Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma , 2005, Cancer.

[270]  J. Olsen,et al.  Cancer risk following primary hemochromatosis: A population‐based cohort study in Denmark , 1995, International journal of cancer.

[271]  J. Machi,et al.  Long-term Follow-up Outcome of Patients Undergoing Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma , 2005, World Journal of Surgery.

[272]  Y. N. Park,et al.  Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. , 1998, The American journal of surgical pathology.

[273]  Y. Cho,et al.  The role of 18F‐FDG‐PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients , 2006 .

[274]  M. Coleman,et al.  Coffee consumption and serum aminotransferases in middle-aged Japanese men. , 2001, Journal of clinical epidemiology.

[275]  F. Nevens,et al.  Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe , 2001, Journal of viral hepatitis.

[276]  Manal M. Hassan,et al.  Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.

[277]  Toshihiko Kanno,et al.  18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma , 2004, Journal of Gastroenterology.

[278]  H. Lien,et al.  Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. , 2005, Cancer letters.

[279]  P. Robinson,et al.  Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. , 2000, Radiology.

[280]  M. Kudo,et al.  Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode. , 2001, Radiology.

[281]  J. Marrero,et al.  Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.

[282]  Wei Cheng,et al.  Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. , 1997, Cancer research.

[283]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[284]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[285]  K. Koito,et al.  Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. , 1998, AJR. American journal of roentgenology.

[286]  Chiung-Nien Chen,et al.  Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. , 2005, Radiology.

[287]  Ding‐Shinn Chen,et al.  Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma: A Prospective Study , 2005, Annals of surgery.

[288]  T. Livraghi,et al.  No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. , 1995, Journal of hepatology.

[289]  Chiung-Nien Chen,et al.  Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma , 2003, Oncology.

[290]  A. Tamori,et al.  Potential role of vitamin K2 as a chemopreventive agent against hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[291]  T. Vogl,et al.  Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. , 2009, European journal of radiology.

[292]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[293]  M. Cottone,et al.  Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis , 2005, Digestive Diseases and Sciences.

[294]  H. Toyoda,et al.  Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma , 1997, Hepatology.

[295]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[296]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[297]  M S Peterson,et al.  From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

[298]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[299]  F. Kruse,et al.  Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[300]  S. Iida,et al.  Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. , 1988, The American journal of gastroenterology.

[301]  坂口 康浩.  Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma , 2006 .

[302]  T. Saibara,et al.  Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1. , 1998, Cancer research.

[303]  J. Willatt,et al.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.

[304]  S. Porru,et al.  Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.

[305]  S. Fan,et al.  Difference in Tumor Invasiveness in Cirrhotic Patients With Hepatocellular Carcinoma Fulfilling the Milan Criteria Treated by Resection and Transplantation: Impact on Long-term Survival , 2007, Annals of surgery.

[306]  M. Mondelli,et al.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study , 1997, Hepatology.

[307]  Chiun Hsu,et al.  Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. , 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

[308]  S. Hirohashi,et al.  Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. , 1991, Human pathology.

[309]  J. Sung,et al.  Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen‐carrier mothers , 1989, JAMA.

[310]  H. Zhuang,et al.  Core promoter mutations (A1762T and G1764A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China , 2002, Journal of medical virology.

[311]  N. Izumi,et al.  Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[312]  M. Kojiro.  Focus on dysplastic nodules and early hepatocellular carcinoma: An Eastern point of view , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[313]  Yi-Cheng Chen,et al.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. , 2004, Gastroenterology.

[314]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[315]  K Takada,et al.  Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. , 2006, Gut.

[316]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[317]  T. Barrientos-Gutiérrez,et al.  Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. , 2006, World journal of gastroenterology.

[318]  Ding‐Shinn Chen,et al.  Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma , 2002, International journal of cancer.

[319]  M. Sherman,et al.  Screening for hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[320]  B. Choi,et al.  Accuracy of detecting hepatocellular carcinomas before liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[321]  E. Bini,et al.  Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. , 2007, Journal of hepatology.

[322]  Shou-Dong Lee,et al.  Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .

[323]  V. Chen,et al.  Screening for Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis: A Cost-Utility Analysis , 2003, American Journal of Gastroenterology.

[324]  A. Benson,et al.  Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[325]  N. Sugiura,et al.  Intratumoral injection of absolute ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma - Attempts in three cases. , 1985 .

[326]  M. Abecassis,et al.  Living donor liver transplantation for hepatocellular carcinoma. , 2004, Gastroenterology.

[327]  K. Suzuki,et al.  Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-aged Japanese men. , 2000, European journal of epidemiology.

[328]  E. Vartiainen,et al.  Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. , 1997, American journal of epidemiology.

[329]  W. Stremmel,et al.  Survival and causes of death in hemochromatosis. Observations in 163 patients. , 1988, Annals of the New York Academy of Sciences.

[330]  Y. Eguchi,et al.  The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment , 2006, Cancer.

[331]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[332]  T. Davern,et al.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[333]  Y. Liaw,et al.  Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma , 2007, Gut.

[334]  Y. Shiratori,et al.  Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus , 2003, Annals of Internal Medicine.

[335]  K. Chayama,et al.  Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.

[336]  H. Asakura,et al.  The usefulness of determining des‐γ‐carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma , 1998, Cancer.

[337]  T. Kawabe,et al.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. , 2005, Gastroenterology.

[338]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[339]  V. Siskind,et al.  Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. , 1985, Journal of the National Cancer Institute.

[340]  G. Klintmalm.  Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. , 1998, Annals of surgery.

[341]  H. Adami,et al.  Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma , 2000, International journal of cancer.

[342]  R. Poon,et al.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. , 1999, Annals of surgery.

[343]  A. Tamori,et al.  Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis , 2001, The Lancet.

[344]  A. Sonnenberg,et al.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. , 1985, The New England journal of medicine.

[345]  T. Takayama,et al.  Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. , 2008, World journal of gastroenterology.

[346]  Kumi Ozaki,et al.  Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. , 2007, Journal of vascular and interventional radiology : JVIR.

[347]  A. Tamori,et al.  Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. , 2001, Annals of internal medicine.

[348]  O. Arrieta,et al.  The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis , 2007, BMC Cancer.

[349]  Ding‐Shinn Chen,et al.  Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. , 2003, Gastroenterology.

[350]  M. Kudo,et al.  Severe Complications of Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: An Analysis of 3,891 Ablations in 2,614 Patients , 2007, Oncology.

[351]  M. Kaito,et al.  Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. , 2002, Hepato-gastroenterology.

[352]  J. Bruix,et al.  Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.

[353]  J. Lee,et al.  F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma , 2007 .

[354]  M. Koike,et al.  Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization , 1995, Cancer.

[355]  C. Chu,et al.  Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. , 2007, Journal of hepatology.

[356]  M. Yuen,et al.  A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma , 2002, Cancer.

[357]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen‐year prospective cohort study , 2007, Hepatology.

[358]  Keitaro Tanaka,et al.  Hepatitis B Virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: A Case‐Control study in Fukuoka, Japan , 1992, International journal of cancer.

[359]  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma , 2001 .

[360]  Fei Liu,et al.  Effects of sho‐saiko‐to, a japanese herbal medicine, on hepatic fibrosis in rats , 1999, Hepatology.

[361]  M. Ebara,et al.  Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. , 1986, Radiology.

[362]  N. Chalasani,et al.  Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey , 1999, American Journal of Gastroenterology.

[363]  T. Yanagisawa,et al.  Selection Criteria for PLIF or TLIF , 2012 .

[364]  G. Ercolani,et al.  Improved Results of Liver Resection for Hepatocellular Carcinoma on Cirrhosis Give the Procedure Added Value , 2001, Annals of surgery.

[365]  T. Ono,et al.  Fucosylation of serum α-fetoprotein in patients with primary hepatocellular carcinoma , 1985 .

[366]  S. Fan,et al.  Improving Perioperative Outcome Expands the Role of Hepatectomy in Management of Benign and Malignant Hepatobiliary Diseases: Analysis of 1222 Consecutive Patients From a Prospective Database , 2004, Annals of surgery.

[367]  Y. Yen,et al.  Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer: A California Cancer Consortium Trial , 2008, American journal of clinical oncology.

[368]  D. Pateron,et al.  Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. , 1994, Journal of hepatology.

[369]  K. Tanaka,et al.  Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. , 1998, International journal of epidemiology.

[370]  S. Hadziyannis,et al.  The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. , 2001, Journal of hepatology.

[371]  S. Kawasaki,et al.  Prognostic significance of anatomical resection and des‐γ‐carboxy prothrombin in patients with hepatocellular carcinoma , 1999, The British journal of surgery.

[372]  A. Zhu.  Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? , 2006, The oncologist.

[373]  A. Craxì,et al.  Prevention of hepatocellular carcinoma. , 2005, Clinics in liver disease.

[374]  Makoto Arai,et al.  Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease , 2003, Hepatology.

[375]  P. Coursaget,et al.  Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. , 1990, Journal of the National Cancer Institute.

[376]  S. Fan,et al.  Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation , 2002, Annals of surgery.

[377]  M. D’Onofrio,et al.  Focal liver lesions: sinusoidal phase of CEUS , 2006, Abdominal Imaging.

[378]  Hung-Ming Wang,et al.  Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma , 2000, Cancer.

[379]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[380]  Junji Konishi,et al.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. , 2002, Radiology.

[381]  F. Moriyasu,et al.  Color Doppler sonography of hepatic tumors with a galactose-based contrast agent: correlation with angiographic findings. , 1994, AJR. American journal of roentgenology.

[382]  E. Hecht,et al.  Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. , 2005, Radiology.

[383]  M. F. F. Ronnie T. P. Poon MBBS.  Optimal Initial Treatment for Early Hepatocellular Carcinoma in Patients with Preserved Liver Function: Transplantation or Resection? , 2006, Annals of Surgical Oncology.

[384]  J. Hoofnagle,et al.  Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. , 1997, Gastroenterology.

[385]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[386]  Jacques Ferlay,et al.  Cancer incidence in five continents. , 1976, IARC scientific publications.

[387]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[388]  M. Omata,et al.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review , 2008, Hepatology international.

[389]  H. Kawasaki,et al.  Effects of Sho‐saiko‐to on hepatocarcinogenesis and 8‐hydroxy‐2'‐deoxyguanosine formation , 2002, Hepatology.

[390]  M. Makuuchi,et al.  Report of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan † , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[391]  S. Shiina,et al.  Percutaneous ethanol injection in the treatment of liver neoplasms. , 1987, AJR. American journal of roentgenology.

[392]  Jane Wang,et al.  Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. , 2004, AJR. American journal of roentgenology.

[393]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[394]  高井 光治.  Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma : updated analysis of the long-term follow-up data , 2005 .

[395]  H. Moriwaki,et al.  Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. , 1999, The New England journal of medicine.

[396]  Osamu Matsui,et al.  Imaging of Multistep Human Hepatocarcinogenesis by CT during Intra-Arterial Contrast Injection , 2004, Intervirology.

[397]  T. Tango,et al.  Prospective study of chemoprevention of hepatocellular carcinoma with sho‐saiko‐to (TJ‐9) , 1995, Cancer.

[398]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[399]  A. Kuijsten,et al.  Population-Attributable Risk of Dietary Aflatoxins and Hepatitis B Virus Infection with Respect to Hepatocellular Carcinoma , 2004, Nutrition and cancer.

[400]  S. Fan,et al.  Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years , 2001, Annals of surgery.

[401]  J. Tsai,et al.  Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. , 1996, British Journal of Cancer.

[402]  J. Heiken,et al.  Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. , 1989, Radiology.

[403]  Young Kon Kim,et al.  Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. , 2006, Radiology.

[404]  H. Groeneveld,et al.  Alcohol consumption as A risk factor for hepatocellular carcinoma in urban Southern African blacks , 1992, International journal of cancer.

[405]  K Arai,et al.  Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. , 1993, Radiology.

[406]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[407]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[408]  D. Amadori,et al.  Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? , 2008 .

[409]  T. Okanoue,et al.  A case‐control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C , 2001, Hepatology.

[410]  Chien-Jen Chen,et al.  Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma , 1991, Hepatology.

[411]  D. Sahani,et al.  Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study , 2008 .

[412]  L. Cavanna,et al.  Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. , 1995, The cancer journal from Scientific American.

[413]  T. Waldmann,et al.  alpha-fetoprotein in noneoplastic hepatic disorders. , 1975, JAMA.

[414]  W. Stremmel,et al.  Survival and Causes of Death in Hemochromatosis , 1988 .

[415]  Y. I. Kim,et al.  Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. , 2001, Radiology.

[416]  M. Kudo,et al.  Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. , 2001, AJR. American journal of roentgenology.

[417]  T. de Baère,et al.  Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) , 2007, Cancer.

[418]  M. Makuuchi,et al.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. , 1999, Archives of surgery.

[419]  D. Harnois.  Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease , 2009 .

[420]  A. Tamori,et al.  Effect of Long-Term Postoperative Interferon Therapy on Intrahepatic Recurrence and Survival Rate after Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma , 2005, Intervirology.

[421]  S. Zeuzem,et al.  Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma , 1999, American Journal of Gastroenterology.

[422]  Giuseppe Brancatelli,et al.  Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. , 2003, AJR. American journal of roentgenology.

[423]  Y. Shiratori,et al.  Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. , 2005, Acta medica Okayama.

[424]  F. Yao,et al.  Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation , 2008, Current opinion in organ transplantation.

[425]  B. Henderson,et al.  Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. , 1991, Journal of the National Cancer Institute.

[426]  P. Robinson,et al.  Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. , 2003, AJR. American journal of roentgenology.

[427]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.